Tetraspanin blockage reduces exosome-mediated HIV-1 entry
- 377 Downloads
HIV-1 is one of the most studied retroviruses. The role of exosomes in HIV-1 entry and pathogenesis are beginning to be appreciated. Exosomes can incorporate host proteins that are also contained in viruses (e.g., tetraspanins).
- HEK 293
Human embryonic kidney cells
T cell immunoglobulin and mucin protein 4
Nanoparticle tracking analysis
Human Immunodeficiency virus-1
cluster of differentiation
infectious molecular clone
HIV-associated neurocognitive disorder
Human immunodeficiency virus-1 (HIV-1) is one of the most studied retroviruses; however, there is still a wealth of information to be learned about this virus’s entry, lifecycle and pathogenesis. The role of exosomes in HIV-1 entry and pathogenesis is beginning to be appreciated. Exosomes are small extracellular vehicles, which traffic nucleic acids (RNA, microRNA, and DNA), proteins, and lipids. Exosomes are secreted by most cell types into the extracellular milieu and then internalized into the recipient cells. It has been well documented that exosomal composition reflects the donor cells in which they are generated. Exosomes can incorporate host proteins that are also contained in viruses (e.g., tetraspanins) [1, 2]. Furthermore, exosomes appear to affect viral infection [3, 4, 5, 6, 7, 8, 9]. It has been previously demonstrated that blocking cluster of differentiation (CD) 9 and CD81 tetraspanins, which are commonly expressed on exosomes, resulted in significant decreases in the exosomal uptake efficiency in dendritic cells . Regarding HIV-1, the role of exosomes in pathogenesis is complex. Studies have shown that exosomes may promote or inhibit HIV-1 infection [11, 12]. The overlap between HIV-1 and exosome biogenesis within an infected cell suggests that HIV-1 products, including RNA and proteins may be encased within exosomes or contaminate exosome preparations from HIV-1 infected fluids [13, 14, 15].
We are just beginning to unravel the complex nature of exosomes and HIV-1 interactions via lipids, phospholipids and proteins [16, 17]. Our group has recently shown that HIV-1 entry into human immune cells is enhanced by exosome-mediated trafficking . This effect was illustrated with exosomes derived from human plasma, human breast milk, mouse neural stem cells and human lung carcinoma cells. Furthermore, our study demonstrated that HIV-1 and exosome interactions were mediated partially through binding of the T cell immunoglobulin and mucin protein 4 (TIM4) to the viral envelope . In this study, we demonstrated that exosomes can enhance HIV-1 entry into human T and monocytic cell lines via exosomal tetraspanin proteins CD81 and CD9.
Materials and Methods
Human CD4+ lymphoblastoid T cell line (line A3R5.7) was a gift from the UAB CFAR Virology core. These cells were commercially received from the NIH AIDS Research and Reference Reagent Program and subsequently genetically modified. A3R5.7 cells were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated, exosome-free fetal bovine serum, 2 mM l-glutamine, penicillin (100 U/mL), streptomycin (100 μg/mL) (Thermo Fisher Scientific, Waltham, MA, USA), and 1 mg/mL geneticin (G418; Thermo Fisher Scientific). Human monocytic cells (line THP2574) were maintained in similar medium but without geneticin [18, 19]. All other cell lines were purchased from American Type Culture Collection.
Isolation of human embryonic kidney cells (HEK 293)-derived exosomes
Cell line HEK293 was grown in DMEM-F12 complete medium containing exosome-free fetal bovine serum to ~80% confluency. In brief, cells were centrifuged at 5,000 rpm for 10 min at 4°C using a Sorvall RT600 centrifuge with a swinging bucket rotor (Thermo Fisher Scientific). The supernatant was clarified by filtration through a 0.22 μm filter and centrifuged at 13,200 rpm for 70 min at 4°C using an SW41T1 swinging rotor in a Beckman Coulter (Brea, CA, USA) Optima L-70K ultracentrifuge for exosome collection [8, 9, 20]. Exosomes were resuspended in 120–450 µL sterile phosphate-buffered saline (PBS) and then quantified by Bradford protein quantitation method.
Isolation of breast milk-derived exosomes
Breast milk samples were retrieved from remnants of breast milk samples from human donors and centrifuged twice at 3,500 rpm for 10 min at 4°C. The fat layer was aspirated and the supernatant transferred to a new tube. A third spin was performed at 5,000 rpm for 30 min at 4°C, after which the remaining fat was aspirated and the supernatant transferred to a new tube. Breast milk was then filtered with a 0.22 µm filter, transferred into an ultracentrifuge tube and then the tube volume was adjusted with PBS prior to an ultracentrifugation spin at 32,000 rpm for 70 min at 4°C. The pellet was collected and resuspended in 120–450 µL sterile PBS.
Isolation of human plasma-derived exosomes
Plasma was collected from whole blood of human donors into tubes containing ethylenediaminetetraacetic acid (EDTA) and processed as described by Konadu et al  with some modifications. Whole-blood samples were centrifuged at 3,500 rpm for 10 min at 4°C. If the samples contained a high lipid content after the low-speed centrifugation (evidenced by color), they were incubated for 2 h at 4°C, and the precipitated fat was removed by centrifugation at 5,000 rpm for 10 min at 4°C. The supernatants were then filtered through a 0.22 μm filter and ultracentrifuged for 30 min at 13,200 rpm in a SW41T1 swinging rotor at 4°C. The pellet was collected by centrifug-ing the samples at 27,000 rpm for 2 h at 4°C. The resulting pellet was resuspended in 1 mL PBS, loaded on to OptiPrep velocity gradients, and subjected to flotation centrifugation at 27,000 rpm for 2 h. Fractions with peak exosome content (fractions 2 and 3) were pooled, diluted with PBS, and ultra-centrifuged for 2 h at 32,000 rpm. The exosome pellet was resuspended in 120 µL PBS.
SDS-PAGE and Western blot analyses of exosome-associated proteins
To analyze proteins associated with exosomes, exosomes were mixed with loading buffer (1:1), boiled, and resolved on a 4%–12% Bis–Tris gel, followed by transfer and blocking on a polyvinylidene difluoride membrane. Blotting was per-formed with two different primary antibodies: anti-clathrin monoclonal antibodies (1:1,000; BD Biosciences, San Jose, CA, USA) and anti-CD81 (1:1,000; System Biosciences, Inc., Palo Alto, CA, USA). Incubation with secondary antibodies was performed using either horseradish peroxidase (HRP)-conjugated goat anti-mouse (1:2,000; Dako Denmark A/S, Glostrup, Denmark) or anti-rabbit (1:20,000; System Biosciences, Inc.) antibodies. Proteins were detected using an enhanced chemiluminescence kit (ELC Western Blotting Substrate Pierce/Thermo Fisher Scientific) and a Bio-Rad ChemiDoc XRS system (Bio-Rad Laboratories, Hercules, CA, USA).
HIV-1 infection of human cell lines
HIV-1 experiments were conducted using an infectious molecular clone (IMC) (NL-LucR.T2A-YU2.ecto [YU-2]) engi-neered to express Renilla luciferase (LucR)  and ENV from the YU-2 virus strain, which was derived from the postmor-tem brain of a patient with HIV-associated neurocognitive disorder (HAND). Throughout this manuscript, this IMC will be referred to as, virus.
A3R5.7 cells were seeded on 96-well plates at a density of 1×105 cells/well with the addition of 5 µg/mL diethylam-inoethyl-dextran . Exosomes derived from NSC, A549, breast milk, and plasma were incubated, respectively, with virus at a multiplicity of infection (MOI) of 0.002 for 1 h at 37°C in 5% CO2,  and then HIV-1/exosome mixture was co-incubated with cells for 72 h at 37°C in 5% CO2. LucR activity was determined using the Renilla Luciferase Assay System (Promega Corporation, Fitchburg, WI, USA). Relative luminescence units (RLUs) were measured in triplicate on a Victor X light luminescence counter (PerkinElmer Inc, Waltham, MA, USA) with an exposure time of 0.1 s/well.
THP2574 cells (1×104 cells/well) were classically differentiated into macrophages with 1 ng/mL phorbol 12-myristate 13-acetate for 96 h. The virus with an MOI of 0.18 was incubated with exosomes for 1 h at 37°C in 5% CO2. The HIV-1/exosome mixture was co-incubated with the cells for 72 h at 37°C in 5% CO2, and LucR activity was measured in triplicate as described earlier.
Amounts of exosomes and viral MOIs used for each cell line were determined experimentally. The following quantities of exosomes, which would saturate all HIV-1 virions, were used for viral entry experiments: 0.035 μg breast milk-derived exosomes, 0.05 μg plasma cell-derived exosomes, and 0.1 μg HEK 293-derived exosomes.
Blocking of HIV-1 infection
A protocol similar to HIV-1 infection was performed but with addition of 0.2 µg/well anti-human CD9 or CD81 (1:1,000; BD Biosciences, San Jose, CA, USA) to the YU-2/exosome/cell incubation. Virus only was used as control.
Determining exosome size and concentration
We used nanoparticle tracking analysis (NTA) using the Nano-Sight LM10 (Malvern Instruments, Inc., Malvern, UK) and NTA v2.0 software to characterize breast milk- and plasma-derived exosomes. All data were collected using five frames and in triplicate. Samples were diluted 1:1,000 prior to tracking, which led to particle sizes of 10−7–10−9 m. Mean values were recorded and analyzed for each given reading frame.
Human study participants
The study was approved by the Institutional Review Board (IRB) for the Protection of Human Subjects in Research at the University of Alabama at Birmingham (UAB) in accordance with approved guidelines and protocol. Breast milk was collected from samples prior to being discarded at the UAB Regional Newborn Intensive Care Unit with expedited IRB approval. Blood donors provided written informed consent prior to donation.
Data represent 12 independent experiments. Significant differences between treatment groups were determined by one-way ANOVA with a post hoc Tukey’s test performed on obtained data points, and results are presented as means ± SEM, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
Isolation and characterization of exosomes
Human-derived exosomes augment HIV-1 entry into cell lines and is subsequently blocked by CD81 antibodies
We previously showed that various exosomes augmented HIV-1 entry in human immune cell lines and this entry was partially blocked by TIM-4 blocking . In this current study, we evaluated the impact of tetraspanins on exosome-mediated HIV-1 entry. We used IMC termed NL-LucR.T2A-YU2.ecto, which was also used in our recent work . Throughout this manuscript, this IMC will be referred to as, virus. To determine the impact of exogenous exosomes (human plasma, breast milk, and HEK 293) on HIV-1 entry and subsequent gene expression, we performed a series of viral infection experiments using exosomes only, virus only, exosomes with virus, or exosomes with virus and anti-CD81 antibody. CD81 blocking experiments were based on previously published experimental dose titrations . The above combinations of molecules were added to either the T lymphoblastoid cell line (A3R5.7) or the macrophage-like cell line (THP2574).
Breast milk-derived exosomes enhance HIV-1 entry and can be blocked using CD9 antibodies
Several biological processes involve tetraspanins such as membrane fusion, cell motility, protein trafficking and cell adhesion, to name a few . Specifically, both CD9 and CD81 are thought to bind with the cytoskeleton via ezrin-radixin-moeisin (ERM) family proteins binding to actin . CD9 and CD81 also have binding partners that are critical for cell adhesion, ICAM-1 and VCAM-1 . Tetraspanins, in particular CD9 and CD81, are found in extracellular vesicles such as exosomes. Thus, it is very plausible that these molecules may be involved in exosome-cellular interactions.
It has been well documented that HIV-1 exploits the exosomal machinery, as reviewed by Madison and Okeoma . We now know the importance of exosomal TIM-4 on viral entry in neural stem cells . We have published that HIV-1 binds to TIM-4 in exosomes and this interaction is associated with enhanced cellular entry . The role of exosomes in HIV-1 pathogenesis is complex and many proteins may be involved, including CD9 and CD81. Based on the current report and our previous studies, it appears all three proteins (TIM-4, CD9 and CD81) are involved. CD9 and CD81 are critical for cell membrane interaction/fusion. CD81 associates with CD4 and is critical for HIV-1 infection . These processes may still be dependent on the specific exosomes involved in exosome-cellular entry.
The role of exosomes in HIV-1 pathogenesis is complex. Näslund and group demonstrated that exosomes from breast milk inhibit HIV-1 infection of dendritic cells and subsequent viral transfer to CD4+ T cells . These findings are different from our findings herein, this may be attributed to the recipient cell types examined in our experiments, T lymphoblastoid cell line or the macrophage-like cell line. In this study, we evaluated exosomes derived from HEK 293 cells to gain some preliminary knowledge related to kidney cell-derived exosomes and their role in mediating HIV-1 entry. To our knowledge, this is the first study in this context. These finding might add to the understanding and further clinical advances of HIV-1 associated nephropathy (HIVAN) which is poorly understood .
A role for CD81 has been identified in HIV-1 budding, cell-to-cell spread and infectivity [1, 28, 29, 32, 33, 34]. It has previously been demonstrated that blocking CD9 and CD81 tetraspanins, which are commonly expressed on exosomes, resulted in significant decreases to exosomal uptake efficiency in dendritic cells . These results are similar to the results we report here. Our current study was designed to evaluate exosome-mediated entry and not virus-antibody interaction. Based on our studies with TIM-4 in exosomes, HIV-1 binds to the exosome and proteins like CD9 and CD81 may then facilitate cellular entry. Research by Luo et al., (2015) revealed the existence of two different forms of exosomes: i) AChE+/CD81 low/TSG101 low exosomes and ii) AChE-/CD81 high/TSG101 high exosomes . We demonstrate that various human-derived exosomes increase the entry of virus and subsequently that this can be blocked with the addition of CD81 and CD9 antibodies, respectively. Manipulating CD81 and CD9 binding to cells may be critical for exosomal entry. Therefore, blocking exosome-mediated uptake of HIV-1 may act as a therapeutic axis to reduce HIV-1 infections, particularly in latent HIV infected targets in immune privilege sites such as the brain.
BS, AB, and QLM contributed to the design of the experiments and the writing of the manuscript. ALF, SDW and AK contributed the to the design and execution of the experiment.
This work was supported by the American Association of Immunologists Careers in Immunology Fellowship Program, Gorgas Memorial Foundation Research Grant Award. National Institutes of Health grant #5R01AI089337-04 and UAB-CCTS grant UL1TR001417, UAB CFAR, an NIH-funded program (P30 AI027767) made possible by the following institutes: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, NIDDK, NIGMS, FIC, and OAR. We are thankful to the scientific support from the UAB CFAR Virology Core, which is part of the UAB CFAR P30-AI-27767. A3R5.7 and THP2574 cell lines were a generous gift from the UAB CFAR Virology Core. We are thankful to the High-Resolution Imaging Facility Service Center who provided NTA. The High-Resolution Imaging Facility is an institutional core at UAB supported by the Office of the Vice President of Research and development and the following grants: Cancer Center Support Grant P30 CA013148 Rheumatic Disease Core Center P30 AR048311. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Compliance with ethical standards
Ethics approval and consent to participate
The study was approved by the Institutional Review Board for the Protection of Human Subjects in Research at the University of Alabama at Birmingham (UAB) in accordance with approved guidelines and protocol. Breast milk was collected from samples prior to being discarded at the UAB Regional Newborn Intensive Care Unit with expedited IRB approval. Blood donors provided written informed consent prior to donation.
The authors have no conflicts of interest to disclose.
Availability of data and material
Please contact author for data requests.
- 10.Kooijmans SA et al (2012) Exosome mimetics: a novel class of drug delivery systems. Int J Nanomed 7:1525–1541Google Scholar
- 20.McDonald MK, Capasso KE, Ajit SK (2013) Purification and microRNA profiling of exosomes derived from blood and culture media. J Vis Exp 76:e50294Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.